New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2014
08:04 EDTNKTRNektar announces dosing of first subject in Phase 1 study for NKTR-171
Nektar Therapeutics announced that the first subjects were dosed in a Phase 1 clinical study for NKTR-171, a new sodium channel blocker being developed as an oral therapy for the treatment of peripheral neuropathic pain.
News For NKTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 21, 2015
09:02 EDTNKTRNektar presents data from study of NKTR-214
Nektar announced positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially stimulate the production and maintenance of tumor-killing T cells which are found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to increase the proliferation of CD8-positive effector T cells, and these CD8-positive T cells comprise a key component of the tumor infiltrating lymphocytes that provide cell-mediated anti-tumor effects. Results were presented this past Friday at the Inaugural CRI-CIMT-EATI-AACR Immunotherapy Conference in New York. NKTR-214 shows efficacy in multiple preclinical models as a single agent. Combination regimens with NKTR-214 and either anti-CTLA4 or anti-PD-1 checkpoint inhibitor therapies resulted in durable anti-tumor immunotherapeutic effects, which persisted long after the termination of dosing.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use